MNMD Stock Overview
Mind Medicine (MindMed) Inc., empresa biofarmacéutica en fase clínica, desarrolla productos novedosos para tratar trastornos de la salud cerebral.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Mind Medicine (MindMed) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.75 |
| 52 Week High | US$12.15 |
| 52 Week Low | US$2.41 |
| Beta | 2.46 |
| 1 Month Change | 88.30% |
| 3 Month Change | 207.59% |
| 1 Year Change | 307.99% |
| 3 Year Change | -70.10% |
| 5 Year Change | n/a |
| Change since IPO | 34.92% |
Recent News & Updates
Recent updates
Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Feb 02Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
May 23
We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely
Feb 07MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics
Oct 19MindMed announces proposed public offering of common shares
Sep 27MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances
Sep 20MindMed regains compliance with Nasdaq's minimum bid price listing requirement
Sep 14MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value
Sep 04Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
Aug 26Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder
Aug 24MindMed soars 71% as it appears to be following in Bed Bath & Beyond's footsteps
Aug 18Mind Medicine GAAP EPS of -$0.04 beats by $0.01
Aug 11Mind Medicine announces 1-for-15 reverse stock split
Aug 04MindMed: Another Psychedelic Medicine Play Trading At A Potential Discount
Jul 12Mind Medicine: It's Best To Stay Far Away From This Risky Psychedelic Stock
Apr 20MindMed: Falling Uncontrollably
Jan 27Shareholder Returns
| MNMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 23.7% | -1.4% | -0.8% |
| 1Y | 308.0% | 17.6% | 26.6% |
Rentabilidad frente al sector: MNMD superó al sector US Pharmaceuticals , que obtuvo un rendimiento del 20.6% el año pasado.
Rentabilidad vs. Mercado: MNMD superó al mercado US, que obtuvo un rendimiento del 22.5% el año pasado.
Price Volatility
| MNMD volatility | |
|---|---|
| MNMD Average Weekly Movement | 19.3% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: MNMDha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: MNMDLa volatilidad semanal ha pasado de 12% a 18% en el último año.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 57 | Rob Barrow | https://www.mindmed.co |
Mind Medicine (MindMed) Inc. es una empresa biofarmacéutica en fase clínica que desarrolla productos novedosos para tratar trastornos cerebrales. Los principales productos candidatos de la empresa son el MM-120, en fase 2 para el tratamiento del trastorno de ansiedad generalizada y el trastorno por déficit de atención con hiperactividad, y el MM-402, un enantiómero R de 3,4-metilendioximetanfetamina, en fase I de ensayos clínicos para el tratamiento de los síntomas básicos del trastorno del espectro autista. Mind Medicine (MindMed) Inc. tiene su sede en Nueva York.
Mind Medicine (MindMed) Inc. Fundamentals Summary
| MNMD fundamental statistics | |
|---|---|
| Market cap | US$828.39m |
| Earnings (TTM) | -US$95.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.7x
P/E RatioIs MNMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$95.73m |
| Earnings | -US$95.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 18.1% |
How did MNMD perform over the long term?
See historical performance and comparison